Gain Ev To Free Cash Flow from 2010 to 2025
| GANX Stock | USD 2.09 0.19 8.33% |
EV To Free Cash Flow | First Reported 2010-12-31 | Previous Quarter (1.51) | Current Value (1.59) | Quarterly Volatility 40.51278328 |
Check Gain Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Gain Therapeutics' main balance sheet or income statement drivers, such as Tax Provision of 172.5 K, Net Interest Income of 666.2 K or Depreciation And Amortization of 100.9 K, as well as many indicators such as Price To Sales Ratio of 842, Dividend Yield of 0.0 or PTB Ratio of 3.2. Gain financial statements analysis is a perfect complement when working with Gain Therapeutics Valuation or Volatility modules.
Gain | Ev To Free Cash Flow |
Latest Gain Therapeutics' Ev To Free Cash Flow Growth Pattern
Below is the plot of the Ev To Free Cash Flow of Gain Therapeutics over the last few years. It is a valuation metric comparing the company's enterprise value to its free cash flow, used to evaluate whether a company is undervalued or overvalued. Gain Therapeutics' EV To Free Cash Flow historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Gain Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Ev To Free Cash Flow | 10 Years Trend |
|
Ev To Free Cash Flow |
| Timeline |
Gain Ev To Free Cash Flow Regression Statistics
| Arithmetic Mean | (57.04) | |
| Geometric Mean | 24.01 | |
| Coefficient Of Variation | (71.03) | |
| Mean Deviation | 36.86 | |
| Median | (88.29) | |
| Standard Deviation | 40.51 | |
| Sample Variance | 1,641 | |
| Range | 86.7831 | |
| R-Value | 0.88 | |
| Mean Square Error | 411.61 | |
| R-Squared | 0.77 | |
| Slope | 7.45 | |
| Total Sum of Squares | 24,619 |
Gain Ev To Free Cash Flow History
About Gain Therapeutics Financial Statements
Gain Therapeutics investors use historical fundamental indicators, such as Gain Therapeutics' Ev To Free Cash Flow, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Gain Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| EV To Free Cash Flow | (1.51) | (1.59) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Additional Tools for Gain Stock Analysis
When running Gain Therapeutics' price analysis, check to measure Gain Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Gain Therapeutics is operating at the current time. Most of Gain Therapeutics' value examination focuses on studying past and present price action to predict the probability of Gain Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Gain Therapeutics' price. Additionally, you may evaluate how the addition of Gain Therapeutics to your portfolios can decrease your overall portfolio volatility.